This site is intended for healthcare professionals outside the US.

  1. Home
  2. aNET
  3. aNET Overview
  4. Overview

EXPERIENCE A NEW PERSPECTIVE IN TUMOR CONTROL

AFINITOR® (everolimus) is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumors (NET) of gastrointestinal or lung origin in adults with progressive disease; and for the treatment of unresectable or metastatic, well- or moderately-differentiated NET of pancreatic origin in adults with progressive disease.

Proven Efficacy
Proven efficacy with AFINITOR Proven efficacy with AFINITOR
AFINITOR offers an established safety profile
AFINITOR offers an established safety profile AFINITOR offers an established safety profile
AFINITOR provides strong evidence backed by multiple phase III studies
Abbreviations:
GI, gastrointestinal; NET, neuroendocrine tumor(s); PFS, progression-free survival; pNET, pancreatic neuroendocrine tumor(s).
References:
  1. AFINITOR [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; August 2017.
  2. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968-977.
  3. Yao JC, Shah MH, Ito T, et al; for the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
  4. Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34(32):3906-3913.